Biotronik announces improved patient outcomes with combination therapy for peripheral artery disease
(Vascular News - www.vascularnews.com)
The 24-month results from the DEBAS clinical trial have been presented at the VEITH Symposium (17–21 November, New York, USA). Biotronik says that DEBAS is the first investigator-initiated trial to demonstrate the efficacy and safety of a novel combination therapy for peripheral artery disease using Passeo-18 Lux drug-coated balloon and Pulsar-18 self-expanding stent to treat peripheral artery disease in a complex patient population.
UPCOMING EVENTS
67th Annual Conference of CSI, Dec. 3-6, 2015, Chennai
22nd Annual Conference of ICC, 18-20 Dec., 2015, Patna
